Hi Hitesh Sir,
If you can share your views on Caplin Point Lab. The company is consistently posting good set of numbers from long period of time even though operating in 75% of drugs in generic category and most of the market covered is unregulated. Now they have forayed into regulated market of USA with one of its subsidiaries. Can we see some sort of re rating or the stock will remain in the same valuation bracket in which it is trading right now?
Thanks.
Subscribe To Our Free Newsletter |